Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis

mAbs

Volumn 3, Issue 4, 2011, Pages 396-401

  Mariotte, Delphine ^a   Dupont, Benoît ^a,b   Gervais, Radj ^c   Galais, Marie Pierre ^c   Laroche, Dominique ^a,b   Tranchant, Aurore ^a   Comby, Elisabeth ^a   Bouhier Leporrier, Karine ^a,c   Reimund, Jean Marie ^a,b   Le Mauff, Brigitte ^a,b,d  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CLCC Centre de Lutte Contre le Cancer François Baclesse   (France)

^d GIP CYCERON   (France)

Author keywords

Anti cetuximab antibodies; ELISA; Hypersensitivity; ROC; Therapeutic monoclonal antibody

Indexed keywords

CETUXIMAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ANTIBODY DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; EVALUATION; IMMUNOLOGY; MIDDLE AGED; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; MICE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK; SENSITIVITY AND SPECIFICITY;

EID: 79960103161     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.4.16293     Document Type: Article

References (25)

1. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 1989; 320:1420-1. (Pubitemid 19138943)
2. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-24. (Pubitemid 29467667)
3. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28. (Pubitemid 44343545)
4. Abramowicz D, Crusiaux A, Niaudet P, Kreis H, Chatenoud L, Goldman M. The IgE humoral response in OKT3-treated patients. Incidence and fine specificity. Transplantation 1996; 61:577-81.
5. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 2002; 74:1697-700. (Pubitemid 36019321)
6. Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76:459-63. (Pubitemid 37013247)
7. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005; 29:31-48. (Pubitemid 41434102)
8. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991; 66:343-7.
9. Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy 2003; 58:688-9. (Pubitemid 36831338)
10. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378-81. (Pubitemid 350216608)
11. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644-8. (Pubitemid 47372602)
12. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized phase II trial of cetuximab, bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61. (Pubitemid 350035312)
13. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008; 358:1109-17. (Pubitemid 351398485)
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45. (Pubitemid 38944402)
15. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78. (Pubitemid 43209104)
16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27.
17. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009; 19:383-7.
18. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18. (Pubitemid 46497948)
19. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 2009;27:4487-91.
20. Jerath MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 2009;123:260-2.
21. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18:963-4. (Pubitemid 47054100)
22. Posthumus J, James H, Wang X, Commins S, Platts-Mills TAE. Correlation of Blood Type with the Presence of IgE Antibodies to Galactose-alpha-1,3-galactose (Alpha-gal): Is there a Protective Effect of Blood Group Substance B? J Allergy Clin Immunol 2010; 125:203.
23. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466-9. (Pubitemid 8045131)
24. Laroche D, Dubois F, Gerard JL, Lefrancois C, Andre B, Vergnaud MC, et al. Radioimmunoassay for plasma histamine: a study of false positive and false negative values. Br J Anaesth 1995; 74:430-7.
25. Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190-204. (Pubitemid 24182179)